Wanbury Ltd

Wanbury Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Wanbury Ltd

₹ 270 -0.33%
08 Jul 2:17 p.m.
wanbury.com BSE: 524212 NSE: WANBURY
About

Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research[1]

Key Points

Business Overview:[1]
WL is a pharmaceutical company with a presence in the API global market and domestic branded Formulation. It’s majorly into Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India
Formulation presence

Website BSE NSE - BE
  • Market Cap ₹ 885 Cr.
  • Current Price ₹ 270
  • High / Low ₹ 330 / 154
  • Stock P/E 29.0
  • Book Value ₹ 18.1
  • Dividend Yield 0.00 %
  • ROCE 34.9 %
  • ROE 70.0 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has delivered good profit growth of 29.8% CAGR over last 5 years

Cons

  • Stock is trading at 14.9 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 10.3% over past five years.
  • Tax rate seems low
  • Promoters have pledged or encumbered 76.7% of their holding.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
134 117 124 126 133 146 144 146 139 131 161 133 172
122 120 118 119 119 133 127 124 121 120 141 120 142
Operating Profit 13 -3 6 6 14 13 17 21 18 11 20 14 30
OPM % 10% -3% 5% 5% 11% 9% 12% 15% 13% 8% 12% 10% 17%
77 2 1 0 -3 1 1 1 1 1 2 1 2
Interest 5 3 4 7 8 6 8 8 7 8 10 10 9
Depreciation 3 3 3 3 3 3 3 3 3 3 3 3 3
Profit before tax 82 -7 -1 -3 1 5 7 10 8 1 8 1 19
Tax % -1% -3% 25% 8% -11% 6% -2% -0% 3% 0% 2% 5% -6%
83 -7 -1 -3 1 5 7 10 8 1 8 1 20
EPS in Rs 25.27 -2.21 -0.27 -1.00 0.31 1.43 2.25 3.14 2.47 0.32 2.45 0.37 6.18
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Sep 2014 18m Mar 2015 6m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
661 250 420 432 370 391 367 392 511 500 576 600
620 228 387 414 438 375 344 374 475 476 506 523
Operating Profit 41 21 34 19 -68 16 23 18 36 23 70 76
OPM % 6% 9% 8% 4% -18% 4% 6% 5% 7% 5% 12% 13%
-237 6 0 90 76 9 84 2 77 0 3 3
Interest 48 19 32 36 31 40 33 23 21 21 29 37
Depreciation 23 5 9 10 10 10 10 10 11 12 13 13
Profit before tax -267 4 -7 62 -32 -25 65 -12 81 -10 31 30
Tax % 1% 28% 0% 1% -1% -1% 0% 2% -0% 1% 1% -3%
-270 3 -7 62 -32 -25 64 -13 81 -10 30 31
EPS in Rs -135.21 1.61 -3.52 26.71 -13.49 -10.48 25.79 -5.04 24.94 -3.18 9.28 9.32
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 9%
5 Years: 10%
3 Years: 5%
TTM: 4%
Compounded Profit Growth
10 Years: 25%
5 Years: 30%
3 Years: 78%
TTM: 2%
Stock Price CAGR
10 Years: 18%
5 Years: 61%
3 Years: 60%
1 Year: 68%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 70%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 20 20 20 23 24 24 25 25 33 33 33 33
Reserves -186 -188 -183 -151 -183 -207 -143 -156 -30 -40 -5 26
389 381 373 273 224 233 164 166 74 68 116 177
182 182 176 265 207 235 231 253 275 241 199 178
Total Liabilities 404 394 386 411 271 285 277 288 351 302 343 414
174 164 180 186 178 172 164 167 167 167 167 201
CWIP 13 19 14 10 10 9 14 11 2 2 3 5
Investments 0 0 0 0 0 0 0 0 0 0 0 0
218 212 192 215 83 103 99 109 182 133 174 208
Total Assets 404 394 386 411 271 285 277 288 351 302 343 414

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
74 40 43 43 32 30 44 17 41 20 4 26
-7 -5 -20 -13 -1 -3 64 8 1 -9 -17 -51
-75 -30 -28 -27 -33 -27 -108 -17 -29 -32 15 26
Net Cash Flow -9 5 -5 3 -2 -0 -0 7 13 -21 2 1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 57 144 65 71 29 41 50 32 45 50 57 70
Inventory Days 42 103 69 63 27 36 25 41 60 26 43 47
Days Payable 112 300 171 259 173 208 252 220 218 178 196 172
Cash Conversion Cycle -13 -54 -37 -124 -117 -131 -176 -147 -112 -101 -96 -55
Working Capital Days -3 -26 -44 -110 -170 -151 -186 -144 -85 -81 -19 13
ROCE % 6% 12% 55% -1% 26% 31% 23% 46% 17% 58% 35%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
39.85% 39.85% 39.84% 39.84% 39.84% 39.80% 39.79% 39.79% 39.79% 39.77% 39.76% 39.76%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.18% 0.22% 1.02% 0.84% 1.55%
60.15% 60.16% 60.16% 60.16% 60.16% 60.19% 60.20% 60.02% 59.97% 59.21% 59.40% 58.68%
No. of Shareholders 11,39811,55511,88811,91111,74111,63411,61613,08714,40017,19917,99917,889

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings